Cardiorenal end points in a trial of aliskiren for type 2 diabetes - Test2 - elhamkhani - TriplyDB

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

http://www.wikidata.org/entity/Q28278569

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Direct renin inhibitors for preventing the progression of diabetic kidney disease 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses Recent advances in treatment of heart failure Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses An Update on the Use of Animal Models in Diabetic Nephropathy Research Can Aliskiren be Considered as a New Novel Drug for Hypertension?Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function Management of diabetic renal disease Updated national and international hypertension guidelines: a review of current recommendations Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis Present and future in the treatment of diabetic kidney disease Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system Mechanisms of disease reversal in focal and segmental glomerulosclerosis Diabetic kidney disease: a report from an ADA Consensus Conference Diabetic kidney disease: from physiology to therapeutics Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease Improvements in the Management of Diabetic Nephropathy Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC)The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis First-line combination therapy versus first-line monotherapy for primary hypertension.Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic.Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials.Clinical therapeutic strategies for early stage of diabetic kidney disease.Heart failure: New data do not SUPPORT triple RAAS blockade.Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders Lipid, blood pressure and kidney update 2013.The impact of antihypertensives on kidney disease.Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring

P2860

Q22241786-8BAAA155-0DD5-4143-B4BB-338E344515A3 Q24198989-BDC71BE8-1F40-4815-A20D-214FDD3C7099 Q26764784-0F367EE1-F1FA-4BC9-9098-1AF68F890E02 Q26765228-BF781349-B157-40A9-B29F-76FA09EBC889 Q26766025-6AE88AB6-6785-41F6-AB24-2C9A607B8903 Q26766223-4428E0A4-BFFE-4463-BE52-AF72F03E85E9 Q26767278-0CC856FA-CD67-476E-BA23-4F8283A12D4C Q26774178-12E6295E-8CEC-4B95-8F20-E48B42DB0344 Q26775106-0176014D-9746-44F2-A0E9-DCBD757533E2 Q26795398-62E5A35C-06B9-4EFF-97C4-5F67B140CFEE Q26798436-6EA7A367-FB1F-4AFB-A47D-5CBBF2AEAB1A Q26824589-CFB62D99-2F1C-45A6-A6C5-68929BBFC8AD Q26863404-E190E7C2-0D3A-4F71-9D8C-1CF2F0FE5372 Q26864133-F4376F2E-AA3D-4062-ABD5-CE58A65587F4 Q26865691-7C270F2D-5197-46B9-9B21-8C702970BBFE Q27010135-5F0AAF8A-23E3-4EC2-9DD5-BEF559AA7E23 Q27012546-C0CCBFBC-1F17-472D-9BA1-459EB98C45EF Q27021392-408CB5C6-1254-4997-9012-4942653E871D Q27314658-85C6C1DC-1337-4CD1-863A-CAB3280B7257 Q28077454-6FC0DE90-5686-4FE9-97D3-B32F3E06114E Q28080717-E04DA28C-F771-4B53-BEE5-99104499AF75 Q28085248-61FBBF7A-96E3-4342-8E7A-0831A49A646B Q28246398-3FF8FE26-5B3D-44B5-8312-97D932CD6B8C Q28354224-50CE9396-C34C-43A0-A220-3D38E6C35B70 Q28387627-2611A7CC-4A65-4E25-BF53-7FD0CFD0C05C Q28543430-838E335F-5762-4EA3-9254-3AA1993DC525 Q29994602-2E0A6546-BFEA-4DF1-A732-A7718C449161 Q30239037-0CE71D58-BB41-48F8-9448-D9EA4837C62B Q30250365-40481CAC-0D95-4DF5-9758-063FB8C08515 Q30251988-C8AF302A-1F7D-4F6E-8BF6-27EB48EA8233 Q30363683-A17777BA-3AE7-4B1C-81C6-FEBAFA53EA23 Q30914698-DD024467-3E48-4599-AC7B-20DCD189588D Q31131772-77B7AA55-E652-4EE2-B85F-DA6066F75E9F Q33166521-B0B6DA90-F733-47CE-95FA-D6BA15402EAC Q33574532-D244993E-E14B-4429-8348-B3FCADA09346 Q33632021-432B72E4-593C-4FBC-90F9-D22998D34D60 Q33633674-E7F908E5-90A3-461F-907C-4B35EEDDC209 Q33799767-86A308FF-9C07-4731-AF5E-3C098F6BCF7E Q33800185-C0D6E9E2-95C2-450F-9155-CF2FAD8934A7 Q33804805-89E371E4-7BAA-427D-B78D-FBE75FCA5382

P2860

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

http://www.wikidata.org/entity/Q28278569

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@ast

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@en

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@nl

type

label

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@ast

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@en

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@nl

prefLabel

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@ast

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@en

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@nl

P1433

Q28278569-DE0BE9E2-BB0E-4FC3-8809-5C06DCA6359E

P1476

Q28278569-C7EB50F0-2A12-4B58-A337-1CE52D3BB28E

P2093

Q28278569-0169CFC9-EC69-4D35-A9CF-7A62F1EA9B2E

Q28278569-05E52733-8895-466E-BAEB-C40EA370FCB7

Q28278569-063C2FC7-EC23-4683-AC77-257D7E5444C2

Q28278569-2D718B36-B953-46B1-A30D-227368950CEF

Q28278569-38458FE0-D2A8-4E93-B1D3-8CA19A85EC10

Q28278569-3D7724A0-65EC-4000-A951-8BCFEC913A7F

Q28278569-68174C6C-394B-49D0-A1F2-907E2B3FF498

Q28278569-B148BB49-C1FC-4386-9D93-760244EDA2AF

Q28278569-C08E1EED-1694-40B4-8D45-4FBC2E357EB3

Q28278569-D8449831-FE3B-49C9-B5C0-D53EF7F9B3B9

P304

Q28278569-CC2C1A1D-31DE-4E7F-A867-3A8E7E9C1EBC

P31

Q28278569-945CF64C-6DFF-44FB-A46F-A0917CFC46F1

P3181

Q28278569-0CA2E2EA-58AA-48C7-A8EB-59B71268E905

P356

Q28278569-61D77D52-DC12-440F-9603-4C7DD125B282

P407

Q28278569-460D98DE-701B-4B79-AEF1-9A9344B4CF10

P433

Q28278569-9563856B-9CAC-46B1-9733-26A57FEE3BFB

P478

Q28278569-48E7474B-AF49-4C96-A9D0-90B0FDE9018F

P50

Q28278569-00B8B348-69D0-4290-837E-19C647664255

Q28278569-663108E4-03F3-403A-A736-00B865435DC9

Q28278569-F09B0D40-9CEB-49B9-A054-6F5633E32ED1

P577

Q28278569-A57D0624-639E-47F5-93E4-C9DCEC5529BA

P698

Q28278569-C29A5203-309D-48A3-9FF3-96A0D697C6EF

P921

Q28278569-9E276D3D-EEBD-4C5B-B04E-8E1A2DC387A1

P3181

P356

P1433

The New England Journal of Medicine

P1476

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

@en

P2093

Akshay S Desai

http://www.w3.org/2001/XMLSchema#string

Alexia Richard

http://www.w3.org/2001/XMLSchema#string

Barry M Brenner

http://www.w3.org/2001/XMLSchema#string

Dick de Zeeuw

http://www.w3.org/2001/XMLSchema#string

Hans-Henrik Parving

http://www.w3.org/2001/XMLSchema#string

Marc A Pfeffer

http://www.w3.org/2001/XMLSchema#string

Maria Nicolaides

http://www.w3.org/2001/XMLSchema#string

Nish Chaturvedi

http://www.w3.org/2001/XMLSchema#string

Patrick Brunel

http://www.w3.org/2001/XMLSchema#string

Scott D Solomon

http://www.w3.org/2001/XMLSchema#string

P304

2204-2213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

957492

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1208799

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Frederik Persson

ESICM H1N1 Registry Contributors

P577

2012-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23121378

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes